Established risk factors for skin cancer include exposure to solar ultraviolet radiation, white race, and advancing age ([@bib4]). Immunosuppression also increases the risk of certain skin cancers. The risk in solid organ transplant recipients and people with human immunodeficiency virus (HIV) infection is extremely high for Kaposi\'s sarcoma (KS), a cutaneous tumour caused by human herpesvirus 8, somewhat elevated for cutaneous non-Hodgkin\'s lymphoma (NHL), Merkel cell carcinoma, and appendageal skin carcinomas and somewhat increased for melanoma ([@bib7]).

Autoimmune conditions may also increase skin cancer risk. Chronic cutaneous inflammation that can characterise some autoimmune conditions (including psoriasis and scleroderma, which directly involve the skin) may plausibly cause DNA damage that could promote development of skin cancer. Immunosuppressive medications used to treat autoimmune conditions could have an additional role. This study aimed to investigate associations between autoimmune conditions and the subsequent risk of skin cancers among elderly US adults (aged 67 years and over).

Materials and methods
=====================

We selected subjects from the Surveillance, Epidemiology, and End Results (SEER)-Medicare data set, which links SEER cancer registry and Medicare claims data ([@bib11]). Skin cancer cases (other than basal and squamous cell carcinomas) and cancer-free controls were selected as described elsewhere ([@bib7]), updated to include SEER Medicare data through 2005. The presence of autoimmune conditions before cancer diagnosis/control selections was assessed using Medicare claims data: rheumatoid arthritis (International Classification of Disease version 9 codes 714.0-714.3, 714.81, V82.1), Sjörgren\'s syndrome (710.2), systemic lupus erythematosus (710.0), polymyalgia rheumatica (725), giant cell arteritis (446.5), Addison\'s disease (255.4), Graves disease (242.0), psoriasis (696.0-696.1), localised scleroderma (701.0), Crohn\'s disease (555), ulcerative colitis (556), and pernicious anaemia (281.0).

We used polytomous logistic regression to derive odds ratios (ORs) comparing the prevalence of each medical condition in skin cancer cases to controls ([@bib7]). We focused on associations that met statistical significance after Benjamini and Hochberg correction to account for multiple comparisons (*P*-value \<0.05, after correction based on 6 skin cancers subtypes × 12 autoimmune conditions=72 tests) ([@bib6]), but we also present uncorrected 95%CIs for ORs that indicate associations of borderline significance (uncorrected *P*-value \<0.05).

Results
=======

Characteristics of 44 613 skin cancer cases and 178 452 controls (corresponding to 134 779 unique control individuals) are shown in [Table 1](#tbl1){ref-type="table"}. Among 1540 appendageal carcinoma cases, the most frequent histological subtypes were sebaceous carcinoma (*N*=610), skin appendage carcinoma (*N*=316), and sweat gland adenocarcinoma (*N*=144). Of the 2652 cutaneous NHLs, 1854 were T-cell NHLs (of which 945 were mycosis fungoides/Sezary syndrome (MF/SS)) and 798 were B-cell NHLs. Among 1324 sarcomas, the most frequent histological subtypes were malignant fibrous histiocytoma (*N*=682), dermatofibrosarcoma (*N*=235), haemangiosarcoma (*N*=173), and leiomyosarcoma (*N*=121).

As shown in [Table 2](#tbl2){ref-type="table"}, an increased risk of Merkel cell carcinoma was observed in persons with rheumatoid arthritis (OR 1.39). Psoriasis was associated with an increased risk of cutaneous NHL (OR 3.20), caused by associations specifically with MF/SS (OR 5.81, 95% CI 4.43--7.63) and other cutaneous T-cell NHLs (OR 2.90, 95% CI 2.07--4.06), whereas cutaneous B-cell NHL risk was not elevated (OR 1.04, 95% CI 0.57--1.89). Ulcerative colitis was associated with risk of KS (OR 2.76), and an increased risk of sarcoma was found with Graves disease (OR 2.62). Among sarcomas, when we considered only malignant fibrous histiocytoma, the association with Graves disease remained significant (OR 3.24, 95% CI 1.33--7.89). Finally, melanoma risk was decreased in individuals with giant cell arteritis (OR 0.70). [Table 2](#tbl2){ref-type="table"} also shows several additional associations of borderline significance.

Discussion
==========

We evaluated the risk of non-keratinocytic skin cancers in patients with autoimmune conditions in a case--control study among elderly US adults. Some associations that met our criterion for significance are likely to be explained by chronic inflammatory involvement of the skin or immune modulating therapies given for autoimmune conditions. The strong association that we observed between psoriasis and T-cell NHL (particularly MF/SS) is a biologically plausible manifestation of chronic inflammation ([@bib3]; [@bib1]). An alternative explanation could be misdiagnosis, in that cutaneous lymphoma can initially present as a chronic plaque-like lesion that might be mistaken for psoriasis ([@bib3]). In contrast, psoriasis was neither associated with cutaneous B-cell NHL nor, in a prior study ([@bib1]), with non-cutaneous T-cell NHL.

Our finding of elevated KS risk associated with ulcerative colitis is supported by several case reports in such patients receiving immunosuppressive drugs ([@bib10]). The association of sarcoma with Graves disease mentioned above may relate to immunosuppressive therapies ([@bib8]), as may that of rheumatoid arthritis with Merkel cell carcinoma, which is increased in HIV-infected people and transplant recipients ([@bib7]) and may be caused by a recently discovered polyomavirus. Finally, we observed an unexpected significant deficit of melanoma among people with giant cell arteritis. A Danish study found no association between autoimmune diseases and melanoma incidence ([@bib5]), although others have reported an increased melanoma risk with pernicious anaemia ([@bib2]) and psoriasis ([@bib9]).

The strength of our study is its large size, allowing us to evaluate associations between uncommon autoimmune conditions and skin cancers. Nonetheless, limitations of our study include that it was restricted to elderly adults, that basal and squamous cell skin cancers were not covered, and that we could not ascertain the presence of medical conditions below 65 years of age; we also had no data on immunosuppressive treatments.

Several associations identified between autoimmune conditions and skin cancer risk suggest that such conditions affecting the skin, or treated with immunosuppression promote the development of skin cancer; their further investigation will require additional large studies.
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###### Characteristics of skin cancer cases and controls among elderly US adults

                                                                                             **Skin cancer cases**                                                                                   
  ---------------------------------------------------------------------- ------------------- ----------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  *Gender, n (%)*                                                                                                                                                                                     
   Male                                                                  109316 (61.3)       22293 (61.8)            1186 (60.0)         785 (51.0)          1478 (55.7)         514 (66.5)          935 (70.6)
   Female                                                                69136 (38.7)        13799 (38.2)            791 (40.0)          755 (49.0)          1174 (44.3)         259 (33.5)          389 (29.4)
                                                                                                                                                                                                      
  *Age in years, n (%)*                                                                                                                                                                               
   67--69                                                                28884 (16.2%)       6142 (17.0%)            182 (9.2%)          186 (12.1%)         443 (16.7%)         82 (10.6%)          158 (11.9%)
   70--74                                                                42792 (24.0%)       8957 (24.9%)            330 (16.7%)         311 (20.2%)         645 (24.3%)         136 (17.6%)         267 (20.2%)
   75--79                                                                43392 (24.3%)       8870 (24.6%)            439 (22.2%)         361 (23.4%)         661 (24.9%)         147 (19.0%)         309 (23.3%)
   80--84                                                                34928 (19.6%)       6838 (18.9%)            512 (25.9%)         317 (20.6%)         516 (19.5%)         171 (22.1%)         320 (24.2%)
   85+                                                                   28456 (15.9%)       5285 (14.6%)            514 (26.0%)         365 (23.7%)         387 (14.6%)         237 (30.7%)         270 (20.4%)
   Median age (years)                                                    76                  76                      80                  78                  76                  80                  79
  Calendar year of diagnosis/ selection, median (IQR)                    2001 (1996--2003)   2001 (1996--2003)       2001 (1997--2003)   2000 (1993--2003)   2000 (1995--2003)   1998 (1993--2002)   2000 (1995--2003)
  Duration of Medicare coverage, months, median (IQR)                    95 (50--150)        93 (49--146)            118 (71--171)       106 (59--161)       93 (50--143)        90 (47--146)        103 (58--156)
  Number of physician claims[a](#t1-fn2){ref-type="fn"}, median (IQR)    37 (6--96)          38 (7--91)              65 (17--138)        51 (9.5--110.5)     40 (7--95)          33 (1--94)          43 (8--102)
  Number of hospital claims[a](#t1-fn2){ref-type="fn"}, median (IQR)     0 (0--2)            0 (0--2)                1 (0--3)            1 (0--2)            0 (0--2)            1 (0--2)            1 (0--2)
  Number of outpatient claims[a](#t1-fn2){ref-type="fn"}, median (IQR)   4 (0--14)           4 (0--13)               6 (1--20)           5 (0--16)           4 (0--14)           2 (0--10)           4 (0--15)

Abbreviations: IQR=interquartile range; KS=Kaposi\'s sarcoma; NHL=non-Hodgkin\'s lymphoma.

The number of claims excludes the 12 months before skin cancer diagnosis (cases) or selection (controls).

###### Associations of autoimmune conditions with skin cancer risk among elderly US adults

                                          **Associations with autoimmune condition: OR (95%CI) and number of subjects with the specified condition**                                                                                                                                                                                                  
  ------------------------------- ------ ------------------------------------------------------------------------------------------------------------ ----------------------------------------------------- --------------------------- ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------
  *Systemic/connective tissue*                                                                                                                                                                                                                                                                                                                        
   Rheumatoid arthritis            2.29                                           0.93 (0.86--1.01) *n*=758                                            1.39 (1.10--1.75)[a](#t2-fn3){ref-type="fn"} *n*=79   1.02 (0.74--1.39) *n*=42                  1.15 (0.90--1.46) *n*=72                               1.65 (1.09--2.49) *n*=25                               1.13 (0.79--1.60) *n*=33
   Sjörgren\'s syndrome            0.21                                            1.00 (0.77--1.30) *n*=73                                                         1.46 (0.72--2.96) *n*\<11                1.76 (0.83--3.74) *n*\<11                1.02 (0.45--2.30) *n*\<11                              0.73 (0.10--5.22) *n*\<11                              1.97 (0.81--4.82) *n*\<11
   Systemic lupus erythematosus    0.20                                            0.80 (0.60--1.06) *n*=57                                                         1.02 (0.42--2.47) *n*\<11                1.62 (0.71--3.66) *n*\<11                1.73 (0.91--3.27) *n*\<11                              1.65 (0.41--6.65) *n*\<11                              0.85 (0.21--3.45) *n*\<11
   Polymyalgia rheumatica          0.97                                           1.04 (0.92--1.17) *n*=353                                                         1.03 (0.71--1.51) *n*=28                 0.90 (0.55--1.46) *n*=17                  0.71 (0.45--1.12) *n*=19                               1.73 (0.99--3.01) *n*=13                              0.74 (0.40--1.40) *n*\<11
                                                                                                                                                                                                                                                                                                                                                                                 
  *Cardiovascular*                                                                                                                                                                                                                                                                                                                                    
   Giant cell arteritis            0.30                              0.70 (0.54--0.90)[a](#t2-fn3){ref-type="fn"} *n*=72                                            1.41 (0.79--2.50) *n*=12                 0.83 (0.34--2.02) *n*\<11                0.85 (0.40--1.80) *n*\<11                              0.87 (0.22--3.50) *n*\<11                              1.50 (0.67--3.38) *n*\<11
                                                                                                                                                                                                                                                                                                                                                                                 
  *Endocrine*                                                                                                                                                                                                                                                                                                                                         
   Addison\'s disease              0.13                                            1.06 (0.77--1.45) *n*=49                                                         0.56 (0.14--2.27) *n*\<11                1.28 (0.41--4.02) *n*\<11                1.13 (0.42--3.05) *n*\<11                              1.98 (0.48--8.15) *n*\<11                              0.53 (0.07--3.83) *n*\<11
   Graves disease                  0.24                                            0.88 (0.68--1.13) *n*=75                                                         1.43 (0.73--2.78) *n*\<11                0.67 (0.21--2.09) *n*\<11                1.20 (0.59--2.43) *n*\<11                                          0                             2.62 (1.30--5.31)[a](#t2-fn3){ref-type="fn"} *n*\<11
                                                                                                                                                                                                                                                                                                                                                                                 
  *Skin*                                                                                                                                                                                                                                                                                                                                              
   Psoriasis                       1.33                                           0.87 (0.78--0.97) *n*=418                                                         1.29 (0.94--1.76) *n*=42                 1.36 (0.94--1.97) *n*=30    3.20 (2.62--3.92)[a](#t2-fn3){ref-type="fn"} *n*=108                 1.20 (0.66--2.21) *n*=11                               0.99 (0.61--1.58) *n*=18
   Localised scleroderma           0.14                                            0.85 (0.60--1.19) *n*=41                                                         1.39 (0.57--3.40) *n*\<11                1.11 (0.35--3.47) *n*\<11                2.06 (1.01--4.19) *n*\<11                              2.34 (0.58--9.45) *n*\<11                              1.27 (0.31--5.15) *n*\<11
                                                                                                                                                                                                                                                                                                                                                                                 
  *Gastrointestinal*                                                                                                                                                                                                                                                                                                                                  
   Crohn\'s disease                0.27                                           1.12 (0.90--1.39) *n*\<116                                                        0.46 (0.15--1.45) *n*\<11                2.25 (1.20--4.23) *n*\<11                1.26 (0.65--2.46) *n*\<11                              1.09 (0.27--4.44) *n*\<11                              0.56 (0.14--2.26) *n*\<11
   Ulcerative colitis              0.48                                           1.08 (0.91--1.27) *n*=183                                                         0.83 (0.44--1.56) *n*\<11                0.98 (0.49--1.98) *n*\<11                 1.34 (0.82--2.17) *n*=17                 2.76 (1.42--5.39)[a](#t2-fn3){ref-type="fn"} *n*\<11                1.24 (0.61--2.49) *n*\<11
   Pernicious anaemia              1.57                                           0.90 (0.81--0.99) *n*=491                                                         0.87 (0.63--1.20) *n*=39                 0.84 (0.56--1.25) *n*=25                  1.05 (0.78--1.43) *n*=44                              0.77 (0.41--1.44) *n*\<11                               1.15 (0.78--1.71) *n*=26

Abbreviations: OR=odds ratio; CI=confidence interval; KS=Kaposi\'s sarcoma; NHL=non-Hodgkin\'s lymphoma.

Odds ratios are adjusted for age (67--69, 70--74, 75--79, 80--84, and 85--99 years), gender, selection year (1987--1993, 1994--1997, 1998--2000, and 2000--2002), and number of physician claims (0--4, 5--39, 40--109, and 110+). For consistency, all odds ratios are displayed to two decimal places, although in some instances the number of subjects with the specified medical condition is small. When the number of subjects with the autoimmune condition was between 1 and 10, the result is listed as '*n*\<11\' to preserve subjects\' anonymity in accordance with the SEER-Medicare data use agreement.

Association was significant after accounting for multiple testing using the Benjamini and Hochberg correction.
